RxDoctor Payments Data

Emile Daoud, MD

Clinical Cardiac Electrophysiology · Cincinnati, OHNPI 1124023437

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Biosense Webster, Inc. at 53.8% of the total. Reporting peaked in 2023 at $14,863 and has fallen 81.0% since, to $2,825 in 2025.

$46,248in general payments, 2019–2025

Across 154 payments — averaging $300.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$25K
  • Biotronik Inc.$6K
  • Medtronic$4K
  • Abbott$3K
  • Boston Scientific$2K
  • Altathera Pharmaceuticals LLC$2K
  • plus $4K from 10 others
$271,168in research payments, 2019–2025

Across 50 payments — averaging $5423.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medical Device Business Services, Inc.$271K
$183,629in ownership & investment interests, 2019–2025

Across 2 payments — averaging $91,815 each. An ownership or investment interest held by the physician or an immediate family member.

  • Anumana, Inc.$184K

What the payments were for

  • Consulting fees$25,27855%
  • Speaking & faculty fees$4,80010%
  • Travel & lodging$9,99322%
  • Food & beverage$6,16313%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$46,248 in reported general payments places this provider in the 80th percentile of 159 clinical cardiac electrophysiology providers in Ohio.

See all clinical cardiac electrophysiology providers in Ohio

Medicare billing

Part B allowed, 2024
$33,637
Medicare patients
368
Services billed
540

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$40,217
XareltoRivaroxaban13$19,488
SotalolSotalol Hcl24$389
Amiodarone Hcl14$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$40,21730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 159 clinical cardiac electrophysiology providers in Ohio.

Other clinical cardiac electrophysiology in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →